image: Morphological and immunohistochemical (PD-1, PD-L1, and CD8) aspects in a patient with AIN1 and AIN3. HES: Hematoxylin, Eosin and Saffron stain for morphological assessment. (A) AIN1 lesion stained with HES. (B) AIN3 lesion stained with HES. (C) CD8 immunostain scored 1 for both band-like infiltrate (arrowheads) and intra-epithelial lymphocytes (arrows) in AIN1 lesion. (D) CD8 immunostain scored 3 and 1 respectively for band-like infiltrate (arrowheads) and intra-epithelial lymphocytes (arrows) in AIN3 lesion. (E) PD-1 immunostain (score 0: no infiltrate) in AIN1 lesion. (F) PD-1 immunostain (score 3: abondant lymphocytic infiltrate) in AIN3 lesion. (G) PD-L1 immunostain (no positive epithelial cells or lymphocytes) in AIN1 lesion. (H) PD-L1 immunostain (40% of PD-L1+ epithelial cells) in AIN3 lesion. The positive cells are large epithelial squamous cells and no lymphocytes are marked. view more
Credit: Correspondence to - Margot Bucau - margot.bucau@aphp.fr
Oncotarget recently published "PD-1/PD-L1 expression in anal squamous intraepithelial lesions" which reported that the presence and distribution of CD8 lymphocytes and the presence of PD-1 lymphocytes and PD-L1 epithelial cells were assessed.
CD8 lymphocytes were observed more frequently in HSIL versus LSIL in the lamina propria or intra epithelial.
PD-1 lymphocytes were observed more frequently in HSIL versus LSIL.
There was no difference between HSIL and LSIL for PD-L1 epithelial cells.
Anal dysplastic lesions are accompanied by an inflammatory lymphocytic infiltrate expressing CD8 and PD-1, more frequent in high-grade lesions.
Dr. Margot Bucau from The Hôpital Bichat-Claude Bernard said, "Anal intraepithelial neoplasia (AIN) is the precursor lesion for anal squamous cell carcinomas (ASCC)."
Dr. Margot Bucau from The Hôpital Bichat-Claude Bernard said, "Anal intraepithelial neoplasia (AIN) is the precursor lesion for anal squamous cell carcinomas (ASCC).
Since 2012, the Lower Anogenital Squamous Terminology recommended denomination for HPV-associated squamous lesions of the lower anogenital tract as low-grade and high-grade squamous intraepithelial lesion.
Oncogenic HPV infection plays a crucial role in developing both cervical and anal lesions, by the integration of the viral DNA into the epithelial cells and activation of oncogenic early proteins E6 and E7. This causes downregulation of suppressing tumor genes, especially TP53 and Rb, and upregulation of p16.
In the cervix, HPV related cancer often have increased infiltration by immune cell populations, including cytotoxic CD8 T cells, that correlates with better response to chemoradiotherapy and increased survival compared to immune-deprived tumors.
Moreover, p16 positive tumors were shown to present higher tumor-infiltrating lymphocytes density and better recurrence-free survival.
The Bucau Research Team concluded in their Oncotarget Research Paper, "our exploratory study highlights the interest of the PD-1/PD-L1 pathway in anal dysplasia and the importance to further explore the different mechanisms of immune micro environment in the progression of anal intra epithelial lesion. It suggests the potential role of therapeutic molecules targeting the immune response to slow down the tumor progression in selected patients with HSIL."
###
DOI - https://doi.org/10.18632/oncotarget.27756Full text - https://www.oncotarget.com/article/27756/text/
Correspondence to - Margot Bucau - margot.bucau@aphp.fr
Keywords - anal dysplasia, PD-L1, HPV, anal cancer, immune microenvironment
About Oncotarget
Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105
Journal
Oncotarget